
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Intravenous sugar solution
Introduction
Overview
Overview
An intravenous sugar solution is a solution with a sugar (usually glucose, a.k.a. dextrose, with water as the solvent) used for intravenous therapy, where it may function both as a means of maintaining tissue hydration and a means of parenteral nutrition.
Types
Types
Types of glucose/dextrose include:
- D5W (5% dextrose in water), which consists of 278Â mmol/L dextrose
- D5NS (5% dextrose in normal saline), which, in addition, contains normal saline (0.90% w/v of NaCl).
- D5 1/2NS (5% dextrose in half amount of normal saline (0.45% w/v of NaCl).[1]
The percentage is a mass percentage, so a 5% glucose/dextrose solution contains 50 mg/ml of glucose/dextrose (Quite simply, 5% dextrose means the solution contains 5g/100ml of solution).
Glucose provides energy 4 kcal/gram, so a 5% glucose solution provides 0.2 kcal/ml. If prepared from dextrose monohydrate, which provides 3.4 kcal/gram, a 5% solution provides 0.17 kcal/ml.[2]
Indications
Indications
Administering a 5% sugar solution peri- and postoperatively usually achieves a good balance between starvation reactions and hyperglycemia caused by sympathetic activation. A 10% solution may be more appropriate when the stress response from the reaction has decreased, after approximately one day after surgery. After more than approximately 2 days, a more complete regimen of total parenteral nutrition is indicated.
In patients with hypernatremia and euvolemia, free water can be replaced using either 5% D/W or 0.45% saline.
References
References
- ↑ eMedicine > Hypernatremia: Treatment & Medication By Ivo Lukitsch and Trung Q Pham. Updated: Apr 19, 2010
- ↑ Calculating Parenteral Feedings D. Chen-Maynard at California State University, San Bernardino. Retrieved September 2010. HSCI 368
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
